Close

Form SC 13G Prenetics Global Ltd Filed by: Genetel Bioventures Ltd

August 17, 2022 4:16 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
(Amendment No.  )*
 

Prenetics Global Limited

(Name of Issuer)
 

Common Stock, par value $0.01 per share

(Title of Class of Securities)
 

G72245106

(CUSIP Number)
 

May 18, 2022

(Date of Event Which Requires Filing of This Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 6 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. G7224510613GPage 2 of 6 Pages

 

1

NAME OF REPORTING PERSON

Genetel Bioventures Limited

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Hong Kong SAR

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

9,206,785

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

9,206,785

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,206,785

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.1%

12

TYPE OF REPORTING PERSON

OO

         

 

 

 

CUSIP No. G7224510613GPage 3 of 6 Pages

 

1

NAME OF REPORTING PERSON

Michael Yang Mengsu

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

China

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

9,206,785

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

9,206,785

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,206,785

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.1%

12

TYPE OF REPORTING PERSON

IN

         

 

CUSIP No. G7224510613GPage 4 of 6 Pages

 

Item 1(a). NAME OF ISSUER:
   
  The name of the issuer is Prenetics Global Limited (the “Company”).  
   
Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
   
  The Company’s principal executive offices are located at Unit 701-706, K11 Atelier King’s Road 728 King’s Road, Quarry Bay, Hong Kong.
   
Item 2(a). NAME OF PERSON FILING:
   
  This Statement is filed on behalf of Genetel Bioventures Limited (“Genetel”), a Hong Kong private limited company and Michael Yang Mengsu (“Mr. Yang Mengsu”), the controlling shareholder of Genetel (collectively, the “Reporting Persons”).
   
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
   
  The principal business office of each of the Reporting Persons is 7B Yardley Commercial Building, 3 Connaught Road West, Sheung Wan, Hong Kong.
   
Item 2(c). CITIZENSHIP:
   
  Genetel is a Hong Kong private limited company. Mr. Yang Mengsu is a citizen of China (Hong Kong SAR).
   
Item 2(d). TITLE OF CLASS OF SECURITIES:
   
  Class A ordinary shares, par value $0.0001 per share (the “Shares”)
   
Item 2(e). CUSIP NUMBER :
   
  G72245106
Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
   
  Not applicable.
   
Item 4. OWNERSHIP:
   
 

The percentage used herein is calculated based upon 101,265,483 Shares outstanding as reported in the Company’s Prospectus filed pursuant to Rule 424(b)(3) with the Securities and Exchange Commission on July 1, 2022.

 

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person and is incorporated herein by reference.

 

The filing of this statement should not be construed as an admission that any Reporting Person is, for the purposes of Sections 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.

 

CUSIP No. G7224510613GPage 5 of 6 Pages

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
   
  If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following:  ¨
   
Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
   
  Not applicable.
   
Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:  
     
  Not applicable.  
     
Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:  
     
  Not applicable.  
     
Item 9. NOTICE OF DISSOLUTION OF GROUP:  
     
  Not applicable.  
     
Item 10. CERTIFICATION:  
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

 

CUSIP No. G7224510613GPage 6 of 6 Pages

 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

DATE: August 17, 2022

 

GENETEL BIOVENTURES LIMITED  
     
By: /s/ George William Hunter Cautherley  
Name: George William Hunter Cautherley  
Title: Director  
     
     
     
By: /s/ Michael Yang Mengsu  
Name: Michael Yang Mengsu  

 

 

 

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

13G